On August 7, 2021, we searched these databases for the terms MAP2K1, MAP2K2, MAP2K3, MAP2K4, MAP2K5, MAP2K6, MAP2K7, and “liver cancer.” The exposure group comprised LIHC patients, and the control group comprised normal patients (those with noncancerous liver tissue). The gene discussed is MAP2K3; the disease is liver cancer.